<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03888677</url>
  </required_header>
  <id_info>
    <org_study_id>SBG 2000-1</org_study_id>
    <nct_id>NCT03888677</nct_id>
  </id_info>
  <brief_title>Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer</brief_title>
  <official_title>SBG 2000-1. Individually Dose-adjusted FEC Compared to Standard FEC as Adjuvant Chemotherapy for Node Positive or High-risk Node Negative Breast Cancer. A Randomized Study by the Scandinavian Breast Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Henrik Lindman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Scandinavian Breast Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Breast Cancer Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharmacia Pharmaceutical Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Swedish Breast Cancer Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open randomized phase III study. The primary objective of this study is to compare&#xD;
      FEC adjuvant chemotherapy in operable breast cancer given either as fixed doses calculated&#xD;
      according to the patients surface area or with doses adjusted according to leukopenia after&#xD;
      course one in order to achieve hematological equitoxicity. The main aim of the study is to&#xD;
      test whether chemotherapy dosage aimed at hematological equitoxicity will improve the effect&#xD;
      of adjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Group A, FECStandard(standard FEC) is given 7 courses of 5-fluorouracil-epirubicin&#xD;
      (Farmorubicin)-cyclophosphamide with doses based on the patient's surface area. Leukocyte&#xD;
      nadir values at day 10, 12 or 13 and 15 are measured. Dose-reductions of one step according&#xD;
      to table 8.2.1 are performed in case of leukopenic fever or grade 4 leukopenia.&#xD;
&#xD;
      Group B FECTailored(Tailored FEC) receives course one at identical doses to group A.&#xD;
      Leukocyte nadir values at day 10,12 or 13 and 15 are measured. Doses of subsequent courses&#xD;
      are adjusted to achieve grade 3 leukopenia (leukocyte nadir 1.0 to 2.0) in patients&#xD;
      experiencing only grade 0 to 2 leukopenia after course one.&#xD;
&#xD;
      Dose-reductions of one step according to table 8.2.1 are performed in case of leukopenic&#xD;
      fever or grade 4 leukopenia .&#xD;
&#xD;
      Patients achieving only grade 0-2 leukopenia at the first course will be randomized into&#xD;
      continued treatment at standard doses (Group A) or to doses tailored to achieve grade 3&#xD;
      leukopenia (Group B). The primary comparisons will be made between these two groups of&#xD;
      patients.&#xD;
&#xD;
      Patients with grade 3-4 leukopenia after the first course not be randomized but followed&#xD;
      according to the protocol and received treatment as group A, FECStandard.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2001</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distant disease-free survival.</measure>
    <time_frame>5-10 years</time_frame>
    <description>Distant disease-free survival comparing standard and tailored arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regio-locally relapsed disease</measure>
    <time_frame>5-10 years</time_frame>
    <description>Regiolocal disease-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5-10 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of treatment.</measure>
    <time_frame>5-10 years</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukopenia and correlation to prognosis in distant disease-free survival.</measure>
    <time_frame>5-10 years.</time_frame>
    <description>Distant disease-free survival in patients groups based on nadir leukopenia after third cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of dose escalation of leukopenia and correlation to prognosis in distant disease-free survival.</measure>
    <time_frame>5-10 years.</time_frame>
    <description>Comparing distant disease-free survival difference between patients randomized to tailored and dose-escalated FEC with the Group of patients with standard FEC but with similar grade of leukopenia.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1535</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard FEC (F600, E60, C600) every 3rd week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tailored</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tailored FEC (F600, E75-90, C900-1200) every 3rd week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Registered</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Non-randomized arm with patients with grade 3-4 leukopenia after first cycle and treated with standard FEC (F600, E60, C600) every 3rd week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU, epirubicin and cyclophosphamide</intervention_name>
    <description>Tailored dose escalation of epirubicin and cyclophosphamide.</description>
    <arm_group_label>Registered</arm_group_label>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_label>Tailored</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Node positive or 2) High-risk node negative#&#xD;
&#xD;
          -  no major cardiovascular morbidity&#xD;
&#xD;
          -  female age 18-60&#xD;
&#xD;
          -  ECOG/WHO performance status &lt;1&#xD;
&#xD;
          -  histologically proven invasive breast cancer&#xD;
&#xD;
          -  written or oral witnessed informed consent according to the local Ethics Committee&#xD;
             requirements&#xD;
&#xD;
          -  start of adjuvant chemotherapy within 8 weeks after surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  distant metastases (M1)&#xD;
&#xD;
          -  locally advanced cancer&#xD;
&#xD;
          -  nonradically operated (positive resection margins)&#xD;
&#xD;
          -  pregnancy or lactation&#xD;
&#xD;
          -  leukocyte count &lt; 3.5 x109 /l&#xD;
&#xD;
          -  platelets &lt; 100 x109 /l&#xD;
&#xD;
          -  other serious medical condition&#xD;
&#xD;
          -  previous or concurrent malignancies at other sites, except basal cell carcinoma and&#xD;
             carcinoma cervicis uteri in situ&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2019</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Uppsala University Hospital</investigator_affiliation>
    <investigator_full_name>Henrik Lindman</investigator_full_name>
    <investigator_title>Senior Consultant, Ass. Professor</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Sharing with EBCTCG (Early Breast Cancer Trialists' Collaborative Group).</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After 5 years.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

